Eli Lilly Buys Ventyx for $1.2B
Eli Lilly announced a $1.2 billion acquisition of Ventyx Biosciences, a strategic move to connect its weight loss drug pipeline with chronic inflammation treatments. The deal aims to capture synergies between the two lucrative markets and fend off growing competition.
The all-cash transaction for Ventyx Biosciences is valued at approximately $1.2 billion, or $14.00 per share. This represents a 62% premium over Ventyx's 30-day volume-weighted average trading price as of January 5, 2026. The deal is anticipated to close in the first half of 2026, pending approval from Ventyx stockholders and other customary regulatory approvals. At the core of the acquisition is Ventyx's pipeline of oral therapeutics targeting inflammatory diseases, particularly its NLRP3 inhibitors. These small molecule drugs are designed to treat a wide range of conditions with significant unmet needs, including cardiometabolic, neurodegenerative, and autoimmune disorders. This move diversifies Eli Lilly's portfolio beyond its successful diabetes and obesity products. The key assets in Ventyx's pipeline include VTX3232, a brain-penetrating NLRP3 inhibitor, and VTX2735, which targets inflammation in the rest of the body. VTX3232 is currently in a Phase 2 trial for obesity and cardiometabolic risk factors, with topline data expected in the second half of 2025. This acquisition strategically bridges Eli Lilly's blockbuster weight-loss drugs, like Zepbound, with the treatment of chronic inflammation. Obesity is widely recognized as a state of chronic low-grade inflammation, which contributes to a variety of other health issues, including cardiovascular disease and insulin resistance. By acquiring Ventyx, Lilly is betting on the therapeutic potential of combining weight-loss management with direct anti-inflammatory treatments.
